GlassScriptPhysician profile
Christopher J Guinand
NPI 1255949996
$2,666.42
in general payments reported to CMS, 2019-2025
31 companies · $951 in 2025
The $951 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $1,415 · 2023: $16.32 · 2024: $33.53 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $548.51 | 2021-2025 | Vyepti |
| Abbvie INC. | $478.13 | 2022-2025 | |
| Nevro Corp. | $208.13 | 2022 | |
| Merz Pharmaceuticals, LLC | $176.35 | 2021-2025 | Xeomin |
| Vertex Pharmaceuticals Incorporated | $153.03 | 2025 | |
| Pfizer INC. | $143.47 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.90 | 2022 | |
| Amgen INC. | $111.50 | 2021-2022 | |
| Globus Medical, INC. | $84.61 | 2025 | Xlif, Tlif, Si-Lok |
| Avanir Pharmaceuticals, INC. | $63.18 | 2022 | |
| Almatica Pharma LLC | $61.66 | 2022 | |
| Ibsa Pharma INC. | $42.46 | 2022 | |
| Fidia Pharma USA INC. | $41.36 | 2022-2025 | Hymovis, Triluron |
| Grt US Holding, INC. | $38.11 | 2022 | |
| Merck Sharp & Dohme LLC | $36.32 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $33.53 | 2024 | Xiaflex |
| Hikma Pharmaceuticals USA | $32.26 | 2021-2022 | |
| Allergan, INC. | $27.04 | 2021 | |
| Biogen, INC. | $26.84 | 2021 | |
| Lilly USA, LLC | $25.94 | 2022 | |
| Collegium Pharmaceutical, INC. | $24.81 | 2022 | |
| Bioventus LLC | $22.20 | 2021 | |
| Tonix Medicines, INC. | $21.65 | 2025 | Tonmya |
| Ipsen Biopharmaceuticals, INC | $21.05 | 2022 | |
| Eisai INC. | $19.82 | 2022 | |
| Si-Bone, INC. | $19.73 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.27 | 2021 | |
| Avanos Medical | $16.63 | 2022 | |
| Averitas Pharma INC. | $16.32 | 2023 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $15.53 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Guinand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.